Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
about
Use of licensed vaccines for active immunization of the immunocompromised hostAntibodies Raised Against Chlamydial Lipopolysaccharide Antigens Reveal Convergence in Germline Gene Usage and Differential Epitope RecognitionCombinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23FIn vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide.Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune miceThe capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyProduction of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci.Antibody interactions with the capsule of Cryptococcus neoformansThe common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoireStructure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci.Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformansAntibody immunity and invasive fungal infectionsOpsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodiesPeptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis.Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.The capsule of the fungal pathogen Cryptococcus neoformans.Lupus-specific antibodies reveal an altered pattern of somatic mutationDecreased mutation frequencies among immunoglobulin G variable region genes during viremic HIV-1 infection.Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.Antifungal activity of a human antiglucuronoxylomannan antibody.Relationship of virulence factor expression to evolved virulence in mouse-passaged Cryptococcus neoformans lines.Binding of glucuronoxylomannan to the CD14 receptor in human A549 alveolar cells induces interleukin-8 production.
P2860
Q24533456-B9638104-3685-4079-A0E2-03A5C299B9FBQ27658569-85AFE549-A313-4F17-8AD1-782641956FCDQ30658618-978A3453-68F4-4158-915E-E46AF6C44817Q34001243-792F0415-852D-4C55-9E58-2F19532FA1F9Q34001504-2A10D980-C9C1-422A-8CC8-7B4DCE7DB977Q34001701-7D3729F8-F872-4B34-BEE5-DC0A927D5115Q34001769-1467D3BD-B966-48F0-9D31-6450DC2C7393Q34003778-1E171135-06E3-4C37-9F82-104F6173AB3AQ34004832-3DD8F466-DBE1-401D-8464-7F82BB78A87BQ34099803-F82214E1-D8A9-4AB9-88D0-B01CDB5EF3E5Q34111761-69D325C8-E991-41F2-B544-F9FAED36D1BBQ34130657-8F3692E9-1FE1-40D0-88EA-EED696A9372CQ35197055-80EAA789-A1DD-4DC6-B372-14A629F4D229Q35447692-532D95EF-474C-4C5E-B3F4-AFCCA57B5C52Q35514947-72F924BB-420A-48B8-8610-F5A7067970F3Q35544888-B26CDAA5-A1F3-466C-9FA2-AB1F5AA4D252Q35546266-DAB514C3-F1FE-4485-8308-74CCC400A8BBQ36228216-6C70AA93-7E89-4BCE-83B2-EB673FD65DFCQ36446429-2A77596E-89F9-4B13-B6F3-F65E5817240BQ36456615-9BB7E325-AB2E-40DF-9335-749F19AD3A95Q37337879-B551E1C8-EF72-4384-A9FC-77BC19F7847DQ37374861-928B3C67-0E23-4345-A4C1-1E4F693C2F5AQ37444828-445F8265-1E70-4290-9634-2D212050796CQ38011299-A72D7EDF-844B-4A5E-9029-9C6F5629707BQ39520077-1D722471-63E5-4779-9B41-0540A94BF897Q39630861-37689697-8760-4687-BF46-0F8E669DFE66Q42254115-9B4B3D18-82B6-4ABB-A8D9-77A1D6EAB018Q42956866-0F55BEEC-D2CA-43D5-9731-B541EB9B83B8
P2860
Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Analysis of human monoclonal a ...... psular polysaccharide vaccine.
@ast
Analysis of human monoclonal a ...... psular polysaccharide vaccine.
@en
type
label
Analysis of human monoclonal a ...... psular polysaccharide vaccine.
@ast
Analysis of human monoclonal a ...... psular polysaccharide vaccine.
@en
prefLabel
Analysis of human monoclonal a ...... psular polysaccharide vaccine.
@ast
Analysis of human monoclonal a ...... psular polysaccharide vaccine.
@en
P2093
P2860
P1476
Analysis of human monoclonal a ...... apsular polysaccharide vaccine
@en
P2093
P2860
P304
P407
P577
1995-08-01T00:00:00Z